Data show how AbCellera is expanding the reach of T-cell engagers with:CD3-binding antibodies that consistently generate T-cell...

AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a ...

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy.

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of...

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue...

Keybanc analyst Scott Schoenhaus initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announ...

New data from AbCellera's T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T...